Surgery News and Research

RSS

Elekta Neuromag TRIUX system unveiled at Organization of Human Brain Mapping's Annual Meeting

At the Organization of Human Brain Mapping's 16th Annual Meeting (Barcelona, Spain, June 6-10), Elekta unveiled its next generation magnetoencephalography system, Elekta Neuromag TRIUX. A platform that addresses key requirements critical for monitoring normal and abnormal brain activity, Elekta Neuromag TRIUX was designed to operate in virtually any clinical environment – an advance welcomed by the growing number of Elekta Neuromag clinical and research facilities worldwide.

From Elekta 7 Jun 2010

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company whose products include BioGlue Surgical Adhesive, announced today that it has completed the purchase of U.S. patent # 6,329,337. The patent involves the formulation and use of recombinant human serum albumin and gluteraldehyde, and now becomes part of CryoLife's protein hydrogel patent portfolio, which includes BioGlue.

7 Jun 2010

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market a 45 mm diameter version of the GORE® TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta. The larger diameter device allows treatment of TAAs with proximal and distal neck diameters ranging from 37 - 42 mm and is now available for commercial use in the U.S.

7 Jun 2010

Viking Systems to demonstrate 3DHD visualization system at The European Congress of Laparoscopy and Robotics

Viking Systems, Inc. announced today that its prototype Next Generation 3DHD Visualization System including Sony's 3DHD display will be demonstrated at The European Congress of Laparoscopy and Robotics allowing attendees an opportunity to participate in an interactive demonstration of the system. This event will be held in Rome, Italy from June 10 through June 12, 2010.

7 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

7 Jun 2010

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

7 Jun 2010

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).

7 Jun 2010

Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010

Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology, highlighted the Phase III trial data presented on June 5 at the American Society of Clinical Oncology's 2010 Annual Meeting, comparing percutaneous hepatic perfusion with melphalan to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma.

7 Jun 2010

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a potentially longer disease-free survival and one-year overall survival in this patient group than reported in previous studies of surgery and adjuvant therapy alone. These data were presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2010

Addition of sorafenib to chemotherapy regimen not effective against advanced melanoma: Study

The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation today at the 46th annual meeting of the American Society of Clinical Oncology in Chicago.

7 Jun 2010

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

Celldex Therapeutics, Inc. today announced that interim results from a Phase 2b study evaluating rindopepimut (formerly PF-04948568 or CDX-110) in newly-diagnosed glioblastoma multiforme (GBM) patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Microplasmin exhibits potential to cure 50% of patients with macular hole

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that further data from the first successful Phase III trial with microplasmin (TG-MV-006) for the non-surgical treatment of vitreomacular adhesion (VMA) were presented at the World Ophthalmology Congress by Dr. Matthew Benz, MD (The Methodist Hospital, Houston, Texas, U.S.)

7 Jun 2010

Selenium not beneficial in reducing risk of lung cancer development

Selenium, a supplement taken daily by millions in hopes of protection against cancer and a host of other diseases, has proven to be of no benefit in reducing a patient's risk of developing lung cancer - either a recurrence or second primary malignancy, according to results of an international Phase III clinical trial.

7 Jun 2010

Bowel cancer affecting more and more Australians

Bowel cancer or colon cancer was till now considered a disease that affected elderly men. Recent trends however show that it is affecting more and more Australians in a younger age group.

6 Jun 2010

US dental school graduates not adequately prepared to screen for sleep disorders

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the majority of U.S. dental schools have not adequately prepared their graduates to screen for sleep disorders, which affect more than 70 million adults in the U.S.

5 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

NewYork-Presbyterian Hospital is the only tri-state-area hospital listed on the 2010 U.S.News & World Report "America's Best Children's Hospitals" "Honor Roll" and one of only eight children's hospitals in the nation to be ranked in all 10 clinical specialties. NewYork-Presbyterian provides children's health services at two major centers: NewYork-Presbyterian/Morgan Stanley Children's Hospital and the Phyllis and David Komansky Center for Children's Health.

5 Jun 2010

Surgery News and Research

Elekta Neuromag TRIUX system unveiled at Organization of Human Brain Mapping's Annual Meeting

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

Viking Systems to demonstrate 3DHD visualization system at The European Congress of Laparoscopy and Robotics

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

Addition of sorafenib to chemotherapy regimen not effective against advanced melanoma: Study

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

Microplasmin exhibits potential to cure 50% of patients with macular hole

Selenium not beneficial in reducing risk of lung cancer development

Bowel cancer affecting more and more Australians

US dental school graduates not adequately prepared to screen for sleep disorders

New clinical research findings on oncology to be highlighted at ASCO 2010

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News